Pandemic must reorient Canada’s pharmaceutical policy away from market-based approach

The federal government should immediately re-establish a public drug and vaccine manufacturer in Canada. This would ensure a resilient domestic supply capacity in the event of future public health emergencies and shortages.

Health Minister Patty Hajdu, pictured during a press briefing on the pandemic. Prime Minister Justin Trudeau has blamed the hollowing out of Canada’s bio-manufacturing sector on his Conservative predecessors, but the situation country faces has been decades in the making. The Hill Times photograph by Andrew Meade

Opinion

BY NDP MP DON DAVIES

February 17, 2021

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy